International pharmaceutical company Galderma has increased its investment in research and innovation, initiating six new Phase III and IV US aesthetic clinical trials.
The six studies include three pivotal trials evaluating XpresHAn Technology products; two studies for Dysport, evaluating patient satisfaction and duration; and one study focusing on the properties of Sculptra Aesthetic, an injectable poly-L-lactic acid.
The company's research and development expansion also includes an increase in the number of women selected as clinical investigators. Since Galderma acquired the US rights to Dysport (abobotulinumtoxinA), Restylane, and Sculptra Aesthetic in 2014, the number of female clinical investigators in company-sponsored trials has increased by more than 50%.
Alisa Lask, general manager and vice president of the US aesthetic business at Galderma, explained, “We are shaping the ever-evolving aesthetics industry like never before by developing new solutions to help drive consumers into aesthetic offices.”
While Xiaoming Lin, global head of aesthetic development at Galderma said, "We understand the vast majority of aesthetics consumers are women, so we have made a significant effort to increase the number of female investigators in our trials.”
New Restylane Lyft dermal filler data was also presented at the American Society for Dermatologic Surgery annual meeting in Phoenix on October 11-14. This included a Phase III study that supported the recent FDA approval of Restylane Lyft for the treatment of age-related volume loss in the hands.